nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Asthenia—Calcium Acetate—osteoporosis	0.00213	0.00359	CcSEcCtD
Metoclopramide—Depression—Risedronate—osteoporosis	0.00209	0.00351	CcSEcCtD
Metoclopramide—Neutropenia—Pamidronate—osteoporosis	0.00209	0.00351	CcSEcCtD
Metoclopramide—Asthma—Zoledronate—osteoporosis	0.00204	0.00343	CcSEcCtD
Metoclopramide—Diarrhoea—Calcium Acetate—osteoporosis	0.00203	0.00342	CcSEcCtD
Metoclopramide—Nervousness—Estropipate—osteoporosis	0.00201	0.00338	CcSEcCtD
Metoclopramide—Bronchospasm—Zoledronate—osteoporosis	0.002	0.00337	CcSEcCtD
Metoclopramide—Muscle spasms—Estropipate—osteoporosis	0.00199	0.00335	CcSEcCtD
Metoclopramide—Confusional state—Etidronic acid—osteoporosis	0.00197	0.00331	CcSEcCtD
Metoclopramide—Dizziness—Calcium Acetate—osteoporosis	0.00197	0.00331	CcSEcCtD
Metoclopramide—Asthma—Conjugated Estrogens—osteoporosis	0.00196	0.0033	CcSEcCtD
Metoclopramide—Muscle spasms—Alendronate—osteoporosis	0.00196	0.0033	CcSEcCtD
Metoclopramide—Bronchospasm—Conjugated Estrogens—osteoporosis	0.00193	0.00325	CcSEcCtD
Metoclopramide—Muscle spasms—Raloxifene—osteoporosis	0.00193	0.00324	CcSEcCtD
Metoclopramide—Visual disturbance—Estradiol—osteoporosis	0.00192	0.00322	CcSEcCtD
Metoclopramide—Muscle spasms—Ibandronate—osteoporosis	0.00191	0.00321	CcSEcCtD
Metoclopramide—Neutropenia—Zoledronate—osteoporosis	0.00191	0.0032	CcSEcCtD
Metoclopramide—Angioedema—Estropipate—osteoporosis	0.00189	0.00318	CcSEcCtD
Metoclopramide—Asthenia—Ergocalciferol—osteoporosis	0.00188	0.00317	CcSEcCtD
Metoclopramide—Pollakiuria—Zoledronate—osteoporosis	0.00188	0.00317	CcSEcCtD
Metoclopramide—Angioedema—Alendronate—osteoporosis	0.00186	0.00313	CcSEcCtD
Metoclopramide—Visual impairment—Ethinyl Estradiol—osteoporosis	0.00186	0.00312	CcSEcCtD
Metoclopramide—Agranulocytosis—Pamidronate—osteoporosis	0.00186	0.00312	CcSEcCtD
Metoclopramide—Palpitations—Estropipate—osteoporosis	0.00183	0.00308	CcSEcCtD
Metoclopramide—Angioedema—Ibandronate—osteoporosis	0.00181	0.00305	CcSEcCtD
Metoclopramide—Depression—Zoledronate—osteoporosis	0.00181	0.00305	CcSEcCtD
Metoclopramide—Agitation—Calcitriol—osteoporosis	0.00179	0.003	CcSEcCtD
Metoclopramide—Nausea—Calcium Acetate—osteoporosis	0.00177	0.00297	CcSEcCtD
Metoclopramide—Anxiety—Estropipate—osteoporosis	0.00176	0.00295	CcSEcCtD
Metoclopramide—Palpitations—Ibandronate—osteoporosis	0.00175	0.00295	CcSEcCtD
Metoclopramide—Depression—Conjugated Estrogens—osteoporosis	0.00174	0.00293	CcSEcCtD
Metoclopramide—Hypertension—Ibandronate—osteoporosis	0.00171	0.00288	CcSEcCtD
Metoclopramide—Agranulocytosis—Zoledronate—osteoporosis	0.0017	0.00285	CcSEcCtD
Metoclopramide—Oedema—Estropipate—osteoporosis	0.00169	0.00284	CcSEcCtD
Metoclopramide—Anxiety—Ibandronate—osteoporosis	0.00168	0.00283	CcSEcCtD
Metoclopramide—Convulsion—Calcitriol—osteoporosis	0.00168	0.00283	CcSEcCtD
Metoclopramide—Hypertension—Calcitriol—osteoporosis	0.00168	0.00282	CcSEcCtD
Metoclopramide—Bradycardia—Zoledronate—osteoporosis	0.00166	0.00279	CcSEcCtD
Metoclopramide—Flushing—Pamidronate—osteoporosis	0.00166	0.00279	CcSEcCtD
Metoclopramide—Anxiety—Calcitriol—osteoporosis	0.00165	0.00277	CcSEcCtD
Metoclopramide—Muscle spasms—Ethinyl Estradiol—osteoporosis	0.00161	0.00271	CcSEcCtD
Metoclopramide—Feeling abnormal—Etidronic acid—osteoporosis	0.00161	0.00271	CcSEcCtD
Metoclopramide—Muscle spasms—Risedronate—osteoporosis	0.00157	0.00264	CcSEcCtD
Metoclopramide—Asthma—Estradiol—osteoporosis	0.00157	0.00264	CcSEcCtD
Metoclopramide—Nausea—Ergocalciferol—osteoporosis	0.00156	0.00262	CcSEcCtD
Metoclopramide—Urticaria—Etidronic acid—osteoporosis	0.00155	0.00261	CcSEcCtD
Metoclopramide—Bronchospasm—Estradiol—osteoporosis	0.00154	0.0026	CcSEcCtD
Metoclopramide—Angioedema—Ethinyl Estradiol—osteoporosis	0.00153	0.00258	CcSEcCtD
Metoclopramide—Insomnia—Estropipate—osteoporosis	0.00153	0.00257	CcSEcCtD
Metoclopramide—Flushing—Zoledronate—osteoporosis	0.00151	0.00255	CcSEcCtD
Metoclopramide—Visual impairment—Conjugated Estrogens—osteoporosis	0.00151	0.00255	CcSEcCtD
Metoclopramide—Nervousness—Pamidronate—osteoporosis	0.00151	0.00254	CcSEcCtD
Metoclopramide—Somnolence—Estropipate—osteoporosis	0.0015	0.00253	CcSEcCtD
Metoclopramide—Muscle spasms—Pamidronate—osteoporosis	0.00149	0.00251	CcSEcCtD
Metoclopramide—Angioedema—Risedronate—osteoporosis	0.00149	0.00251	CcSEcCtD
Metoclopramide—Insomnia—Raloxifene—osteoporosis	0.00148	0.00249	CcSEcCtD
Metoclopramide—Insomnia—Ibandronate—osteoporosis	0.00146	0.00246	CcSEcCtD
Metoclopramide—Fatigue—Estropipate—osteoporosis	0.00146	0.00245	CcSEcCtD
Metoclopramide—Pollakiuria—Estradiol—osteoporosis	0.00145	0.00244	CcSEcCtD
Metoclopramide—Hypersensitivity—Etidronic acid—osteoporosis	0.00144	0.00242	CcSEcCtD
Metoclopramide—Insomnia—Calcitriol—osteoporosis	0.00143	0.00241	CcSEcCtD
Metoclopramide—Agitation—Pamidronate—osteoporosis	0.00143	0.0024	CcSEcCtD
Metoclopramide—Anxiety—Ethinyl Estradiol—osteoporosis	0.00142	0.00239	CcSEcCtD
Metoclopramide—Angioedema—Pamidronate—osteoporosis	0.00142	0.00239	CcSEcCtD
Metoclopramide—Hypertension—Risedronate—osteoporosis	0.00141	0.00237	CcSEcCtD
Metoclopramide—Somnolence—Calcitriol—osteoporosis	0.00141	0.00237	CcSEcCtD
Metoclopramide—Depression—Estradiol—osteoporosis	0.0014	0.00235	CcSEcCtD
Metoclopramide—Fatigue—Ibandronate—osteoporosis	0.0014	0.00235	CcSEcCtD
Metoclopramide—Leukopenia—Pamidronate—osteoporosis	0.00139	0.00234	CcSEcCtD
Metoclopramide—Anxiety—Risedronate—osteoporosis	0.00139	0.00233	CcSEcCtD
Metoclopramide—Feeling abnormal—Alendronate—osteoporosis	0.00137	0.00231	CcSEcCtD
Metoclopramide—Oedema—Ethinyl Estradiol—osteoporosis	0.00137	0.0023	CcSEcCtD
Metoclopramide—Muscle spasms—Zoledronate—osteoporosis	0.00137	0.0023	CcSEcCtD
Metoclopramide—Jaundice—Estradiol—osteoporosis	0.00137	0.0023	CcSEcCtD
Metoclopramide—Convulsion—Pamidronate—osteoporosis	0.00135	0.00227	CcSEcCtD
Metoclopramide—Hypertension—Pamidronate—osteoporosis	0.00134	0.00226	CcSEcCtD
Metoclopramide—Urticaria—Estropipate—osteoporosis	0.00134	0.00226	CcSEcCtD
Metoclopramide—Diarrhoea—Etidronic acid—osteoporosis	0.00134	0.00225	CcSEcCtD
Metoclopramide—Body temperature increased—Estropipate—osteoporosis	0.00134	0.00225	CcSEcCtD
Metoclopramide—Feeling abnormal—Ibandronate—osteoporosis	0.00133	0.00224	CcSEcCtD
Metoclopramide—Tremor—Zoledronate—osteoporosis	0.00133	0.00224	CcSEcCtD
Metoclopramide—Nervousness—Conjugated Estrogens—osteoporosis	0.00133	0.00223	CcSEcCtD
Metoclopramide—Urticaria—Alendronate—osteoporosis	0.00132	0.00222	CcSEcCtD
Metoclopramide—Anxiety—Pamidronate—osteoporosis	0.00132	0.00222	CcSEcCtD
Metoclopramide—Body temperature increased—Alendronate—osteoporosis	0.00132	0.00221	CcSEcCtD
Metoclopramide—Muscle spasms—Conjugated Estrogens—osteoporosis	0.00131	0.00221	CcSEcCtD
Metoclopramide—Agitation—Zoledronate—osteoporosis	0.00131	0.00219	CcSEcCtD
Metoclopramide—Angioedema—Zoledronate—osteoporosis	0.0013	0.00218	CcSEcCtD
Metoclopramide—Body temperature increased—Raloxifene—osteoporosis	0.00129	0.00217	CcSEcCtD
Metoclopramide—Urticaria—Ibandronate—osteoporosis	0.00129	0.00216	CcSEcCtD
Metoclopramide—Body temperature increased—Ibandronate—osteoporosis	0.00128	0.00215	CcSEcCtD
Metoclopramide—Confusional state—Pamidronate—osteoporosis	0.00128	0.00215	CcSEcCtD
Metoclopramide—Leukopenia—Zoledronate—osteoporosis	0.00127	0.00214	CcSEcCtD
Metoclopramide—Oedema—Pamidronate—osteoporosis	0.00127	0.00213	CcSEcCtD
Metoclopramide—Urticaria—Calcitriol—osteoporosis	0.00126	0.00212	CcSEcCtD
Metoclopramide—Palpitations—Zoledronate—osteoporosis	0.00125	0.00211	CcSEcCtD
Metoclopramide—Body temperature increased—Calcitriol—osteoporosis	0.00125	0.00211	CcSEcCtD
Metoclopramide—Angioedema—Conjugated Estrogens—osteoporosis	0.00125	0.0021	CcSEcCtD
Metoclopramide—Hypersensitivity—Estropipate—osteoporosis	0.00124	0.00209	CcSEcCtD
Metoclopramide—Tachycardia—Pamidronate—osteoporosis	0.00124	0.00208	CcSEcCtD
Metoclopramide—Rash—Etidronic acid—osteoporosis	0.00123	0.00207	CcSEcCtD
Metoclopramide—Convulsion—Zoledronate—osteoporosis	0.00123	0.00207	CcSEcCtD
Metoclopramide—Dermatitis—Etidronic acid—osteoporosis	0.00123	0.00207	CcSEcCtD
Metoclopramide—Hypertension—Zoledronate—osteoporosis	0.00123	0.00206	CcSEcCtD
Metoclopramide—Hypersensitivity—Alendronate—osteoporosis	0.00123	0.00206	CcSEcCtD
Metoclopramide—Headache—Etidronic acid—osteoporosis	0.00122	0.00206	CcSEcCtD
Metoclopramide—Asthenia—Estropipate—osteoporosis	0.00121	0.00204	CcSEcCtD
Metoclopramide—Visual impairment—Estradiol—osteoporosis	0.00121	0.00204	CcSEcCtD
Metoclopramide—Palpitations—Conjugated Estrogens—osteoporosis	0.00121	0.00203	CcSEcCtD
Metoclopramide—Insomnia—Risedronate—osteoporosis	0.00121	0.00203	CcSEcCtD
Metoclopramide—Anxiety—Zoledronate—osteoporosis	0.0012	0.00203	CcSEcCtD
Metoclopramide—Asthenia—Alendronate—osteoporosis	0.00119	0.00201	CcSEcCtD
Metoclopramide—Hypersensitivity—Ibandronate—osteoporosis	0.00119	0.00201	CcSEcCtD
Metoclopramide—Dyspnoea—Risedronate—osteoporosis	0.00119	0.002	CcSEcCtD
Metoclopramide—Hypotension—Pamidronate—osteoporosis	0.00119	0.00199	CcSEcCtD
Metoclopramide—Convulsion—Conjugated Estrogens—osteoporosis	0.00118	0.00199	CcSEcCtD
Metoclopramide—Fatigue—Ethinyl Estradiol—osteoporosis	0.00118	0.00198	CcSEcCtD
Metoclopramide—Confusional state—Zoledronate—osteoporosis	0.00117	0.00197	CcSEcCtD
Metoclopramide—Hypersensitivity—Calcitriol—osteoporosis	0.00117	0.00196	CcSEcCtD
Metoclopramide—Flushing—Estradiol—osteoporosis	0.00117	0.00196	CcSEcCtD
Metoclopramide—Asthenia—Ibandronate—osteoporosis	0.00116	0.00195	CcSEcCtD
Metoclopramide—Anxiety—Conjugated Estrogens—osteoporosis	0.00116	0.00195	CcSEcCtD
Metoclopramide—Nausea—Etidronic acid—osteoporosis	0.00116	0.00195	CcSEcCtD
Metoclopramide—Oedema—Zoledronate—osteoporosis	0.00116	0.00195	CcSEcCtD
Metoclopramide—Diarrhoea—Estropipate—osteoporosis	0.00116	0.00194	CcSEcCtD
Metoclopramide—Fatigue—Risedronate—osteoporosis	0.00115	0.00194	CcSEcCtD
Metoclopramide—Insomnia—Pamidronate—osteoporosis	0.00115	0.00193	CcSEcCtD
Metoclopramide—Diarrhoea—Alendronate—osteoporosis	0.00114	0.00191	CcSEcCtD
Metoclopramide—Asthenia—Calcitriol—osteoporosis	0.00114	0.00191	CcSEcCtD
Metoclopramide—Dyspnoea—Pamidronate—osteoporosis	0.00113	0.0019	CcSEcCtD
Metoclopramide—Tachycardia—Zoledronate—osteoporosis	0.00113	0.0019	CcSEcCtD
Metoclopramide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00113	0.0019	CcSEcCtD
Metoclopramide—Somnolence—Pamidronate—osteoporosis	0.00113	0.0019	CcSEcCtD
Metoclopramide—Diarrhoea—Raloxifene—osteoporosis	0.00112	0.00188	CcSEcCtD
Metoclopramide—Dizziness—Estropipate—osteoporosis	0.00112	0.00188	CcSEcCtD
Metoclopramide—Oedema—Conjugated Estrogens—osteoporosis	0.00112	0.00188	CcSEcCtD
Metoclopramide—Diarrhoea—Ibandronate—osteoporosis	0.00111	0.00186	CcSEcCtD
Metoclopramide—Dizziness—Alendronate—osteoporosis	0.0011	0.00185	CcSEcCtD
Metoclopramide—Fatigue—Pamidronate—osteoporosis	0.00109	0.00184	CcSEcCtD
Metoclopramide—Tachycardia—Conjugated Estrogens—osteoporosis	0.00109	0.00183	CcSEcCtD
Metoclopramide—Urticaria—Ethinyl Estradiol—osteoporosis	0.00109	0.00183	CcSEcCtD
Metoclopramide—Diarrhoea—Calcitriol—osteoporosis	0.00108	0.00182	CcSEcCtD
Metoclopramide—Hypotension—Zoledronate—osteoporosis	0.00108	0.00182	CcSEcCtD
Metoclopramide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00108	0.00182	CcSEcCtD
Metoclopramide—Dizziness—Raloxifene—osteoporosis	0.00108	0.00182	CcSEcCtD
Metoclopramide—Dizziness—Ibandronate—osteoporosis	0.00107	0.0018	CcSEcCtD
Metoclopramide—Rash—Estropipate—osteoporosis	0.00106	0.00179	CcSEcCtD
Metoclopramide—Dermatitis—Estropipate—osteoporosis	0.00106	0.00179	CcSEcCtD
Metoclopramide—Nervousness—Estradiol—osteoporosis	0.00106	0.00179	CcSEcCtD
Metoclopramide—Urticaria—Risedronate—osteoporosis	0.00106	0.00178	CcSEcCtD
Metoclopramide—Headache—Estropipate—osteoporosis	0.00106	0.00178	CcSEcCtD
Metoclopramide—Body temperature increased—Risedronate—osteoporosis	0.00106	0.00177	CcSEcCtD
Metoclopramide—Muscle spasms—Estradiol—osteoporosis	0.00105	0.00177	CcSEcCtD
Metoclopramide—Rash—Alendronate—osteoporosis	0.00105	0.00176	CcSEcCtD
Metoclopramide—Insomnia—Zoledronate—osteoporosis	0.00105	0.00176	CcSEcCtD
Metoclopramide—Dermatitis—Alendronate—osteoporosis	0.00105	0.00176	CcSEcCtD
Metoclopramide—Feeling abnormal—Pamidronate—osteoporosis	0.00105	0.00176	CcSEcCtD
Metoclopramide—Hypotension—Conjugated Estrogens—osteoporosis	0.00104	0.00175	CcSEcCtD
Metoclopramide—Headache—Alendronate—osteoporosis	0.00104	0.00175	CcSEcCtD
Metoclopramide—Dyspnoea—Zoledronate—osteoporosis	0.00103	0.00174	CcSEcCtD
Metoclopramide—Rash—Raloxifene—osteoporosis	0.00103	0.00173	CcSEcCtD
Metoclopramide—Dermatitis—Raloxifene—osteoporosis	0.00103	0.00173	CcSEcCtD
Metoclopramide—Somnolence—Zoledronate—osteoporosis	0.00103	0.00173	CcSEcCtD
Metoclopramide—Tremor—Estradiol—osteoporosis	0.00103	0.00172	CcSEcCtD
Metoclopramide—Headache—Raloxifene—osteoporosis	0.00102	0.00172	CcSEcCtD
Metoclopramide—Rash—Ibandronate—osteoporosis	0.00102	0.00172	CcSEcCtD
Metoclopramide—Dermatitis—Ibandronate—osteoporosis	0.00102	0.00172	CcSEcCtD
Metoclopramide—Headache—Ibandronate—osteoporosis	0.00101	0.00171	CcSEcCtD
Metoclopramide—Insomnia—Conjugated Estrogens—osteoporosis	0.00101	0.0017	CcSEcCtD
Metoclopramide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00101	0.0017	CcSEcCtD
Metoclopramide—Agitation—Estradiol—osteoporosis	0.00101	0.00169	CcSEcCtD
Metoclopramide—Nausea—Estropipate—osteoporosis	0.001	0.00169	CcSEcCtD
Metoclopramide—Body temperature increased—Pamidronate—osteoporosis	0.001	0.00169	CcSEcCtD
Metoclopramide—Angioedema—Estradiol—osteoporosis	0.001	0.00168	CcSEcCtD
Metoclopramide—Rash—Calcitriol—osteoporosis	0.001	0.00168	CcSEcCtD
Metoclopramide—Fatigue—Zoledronate—osteoporosis	0.000999	0.00168	CcSEcCtD
Metoclopramide—Dermatitis—Calcitriol—osteoporosis	0.000999	0.00168	CcSEcCtD
Metoclopramide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000995	0.00167	CcSEcCtD
Metoclopramide—Headache—Calcitriol—osteoporosis	0.000993	0.00167	CcSEcCtD
Metoclopramide—Somnolence—Conjugated Estrogens—osteoporosis	0.000992	0.00167	CcSEcCtD
Metoclopramide—Nausea—Alendronate—osteoporosis	0.000988	0.00166	CcSEcCtD
Metoclopramide—Hypersensitivity—Risedronate—osteoporosis	0.000983	0.00165	CcSEcCtD
Metoclopramide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000982	0.00165	CcSEcCtD
Metoclopramide—Nausea—Raloxifene—osteoporosis	0.000972	0.00163	CcSEcCtD
Metoclopramide—Palpitations—Estradiol—osteoporosis	0.000967	0.00163	CcSEcCtD
Metoclopramide—Fatigue—Conjugated Estrogens—osteoporosis	0.000962	0.00162	CcSEcCtD
Metoclopramide—Nausea—Ibandronate—osteoporosis	0.000962	0.00162	CcSEcCtD
Metoclopramide—Asthenia—Risedronate—osteoporosis	0.000958	0.00161	CcSEcCtD
Metoclopramide—Feeling abnormal—Zoledronate—osteoporosis	0.000955	0.00161	CcSEcCtD
Metoclopramide—Hypertension—Estradiol—osteoporosis	0.000945	0.00159	CcSEcCtD
Metoclopramide—Nausea—Calcitriol—osteoporosis	0.000942	0.00158	CcSEcCtD
Metoclopramide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000937	0.00158	CcSEcCtD
Metoclopramide—Hypersensitivity—Pamidronate—osteoporosis	0.000935	0.00157	CcSEcCtD
Metoclopramide—Anxiety—Estradiol—osteoporosis	0.000929	0.00156	CcSEcCtD
Metoclopramide—Urticaria—Zoledronate—osteoporosis	0.000921	0.00155	CcSEcCtD
Metoclopramide—Body temperature increased—Zoledronate—osteoporosis	0.000916	0.00154	CcSEcCtD
Metoclopramide—Diarrhoea—Risedronate—osteoporosis	0.000913	0.00154	CcSEcCtD
Metoclopramide—Asthenia—Pamidronate—osteoporosis	0.00091	0.00153	CcSEcCtD
Metoclopramide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000905	0.00152	CcSEcCtD
Metoclopramide—Confusional state—Estradiol—osteoporosis	0.000901	0.00151	CcSEcCtD
Metoclopramide—Oedema—Estradiol—osteoporosis	0.000893	0.0015	CcSEcCtD
Metoclopramide—Urticaria—Conjugated Estrogens—osteoporosis	0.000887	0.00149	CcSEcCtD
Metoclopramide—Dizziness—Risedronate—osteoporosis	0.000883	0.00148	CcSEcCtD
Metoclopramide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000882	0.00148	CcSEcCtD
Metoclopramide—Tachycardia—Estradiol—osteoporosis	0.000872	0.00147	CcSEcCtD
Metoclopramide—Diarrhoea—Pamidronate—osteoporosis	0.000868	0.00146	CcSEcCtD
Metoclopramide—Rash—Ethinyl Estradiol—osteoporosis	0.000863	0.00145	CcSEcCtD
Metoclopramide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000862	0.00145	CcSEcCtD
Metoclopramide—Headache—Ethinyl Estradiol—osteoporosis	0.000858	0.00144	CcSEcCtD
Metoclopramide—Hypersensitivity—Zoledronate—osteoporosis	0.000854	0.00144	CcSEcCtD
Metoclopramide—Rash—Risedronate—osteoporosis	0.000842	0.00142	CcSEcCtD
Metoclopramide—Dermatitis—Risedronate—osteoporosis	0.000841	0.00141	CcSEcCtD
Metoclopramide—Dizziness—Pamidronate—osteoporosis	0.000839	0.00141	CcSEcCtD
Metoclopramide—Headache—Risedronate—osteoporosis	0.000836	0.00141	CcSEcCtD
Metoclopramide—Asthenia—Zoledronate—osteoporosis	0.000832	0.0014	CcSEcCtD
Metoclopramide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000822	0.00138	CcSEcCtD
Metoclopramide—Nausea—Ethinyl Estradiol—osteoporosis	0.000813	0.00137	CcSEcCtD
Metoclopramide—Insomnia—Estradiol—osteoporosis	0.000808	0.00136	CcSEcCtD
Metoclopramide—Asthenia—Conjugated Estrogens—osteoporosis	0.000801	0.00135	CcSEcCtD
Metoclopramide—Rash—Pamidronate—osteoporosis	0.0008	0.00135	CcSEcCtD
Metoclopramide—Dermatitis—Pamidronate—osteoporosis	0.000799	0.00134	CcSEcCtD
Metoclopramide—Dyspnoea—Estradiol—osteoporosis	0.000796	0.00134	CcSEcCtD
Metoclopramide—Headache—Pamidronate—osteoporosis	0.000795	0.00134	CcSEcCtD
Metoclopramide—Somnolence—Estradiol—osteoporosis	0.000794	0.00134	CcSEcCtD
Metoclopramide—Diarrhoea—Zoledronate—osteoporosis	0.000793	0.00133	CcSEcCtD
Metoclopramide—Nausea—Risedronate—osteoporosis	0.000793	0.00133	CcSEcCtD
Metoclopramide—Fatigue—Estradiol—osteoporosis	0.00077	0.00129	CcSEcCtD
Metoclopramide—Dizziness—Zoledronate—osteoporosis	0.000766	0.00129	CcSEcCtD
Metoclopramide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000764	0.00128	CcSEcCtD
Metoclopramide—Nausea—Pamidronate—osteoporosis	0.000754	0.00127	CcSEcCtD
Metoclopramide—Dizziness—Conjugated Estrogens—osteoporosis	0.000738	0.00124	CcSEcCtD
Metoclopramide—Feeling abnormal—Estradiol—osteoporosis	0.000736	0.00124	CcSEcCtD
Metoclopramide—Rash—Zoledronate—osteoporosis	0.000731	0.00123	CcSEcCtD
Metoclopramide—Dermatitis—Zoledronate—osteoporosis	0.00073	0.00123	CcSEcCtD
Metoclopramide—Headache—Zoledronate—osteoporosis	0.000726	0.00122	CcSEcCtD
Metoclopramide—Urticaria—Estradiol—osteoporosis	0.00071	0.00119	CcSEcCtD
Metoclopramide—Body temperature increased—Estradiol—osteoporosis	0.000706	0.00119	CcSEcCtD
Metoclopramide—Rash—Conjugated Estrogens—osteoporosis	0.000704	0.00118	CcSEcCtD
Metoclopramide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000703	0.00118	CcSEcCtD
Metoclopramide—Headache—Conjugated Estrogens—osteoporosis	0.000699	0.00118	CcSEcCtD
Metoclopramide—Nausea—Zoledronate—osteoporosis	0.000688	0.00116	CcSEcCtD
Metoclopramide—Nausea—Conjugated Estrogens—osteoporosis	0.000663	0.00111	CcSEcCtD
Metoclopramide—Hypersensitivity—Estradiol—osteoporosis	0.000658	0.00111	CcSEcCtD
Metoclopramide—Asthenia—Estradiol—osteoporosis	0.000641	0.00108	CcSEcCtD
Metoclopramide—Diarrhoea—Estradiol—osteoporosis	0.000611	0.00103	CcSEcCtD
Metoclopramide—Dizziness—Estradiol—osteoporosis	0.000591	0.000993	CcSEcCtD
Metoclopramide—Rash—Estradiol—osteoporosis	0.000563	0.000947	CcSEcCtD
Metoclopramide—Dermatitis—Estradiol—osteoporosis	0.000563	0.000946	CcSEcCtD
Metoclopramide—Headache—Estradiol—osteoporosis	0.00056	0.000941	CcSEcCtD
Metoclopramide—Nausea—Estradiol—osteoporosis	0.000531	0.000892	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—TPI1—osteoporosis	0.000282	0.000697	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—MGLL—osteoporosis	0.000282	0.000696	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PSMA2—osteoporosis	0.00028	0.000692	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PSMA5—osteoporosis	0.00028	0.000692	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GAPDH—osteoporosis	0.000279	0.000687	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—MGLL—osteoporosis	0.000276	0.000682	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SOST—osteoporosis	0.000275	0.00068	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—LEP—osteoporosis	0.000275	0.000678	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000275	0.000678	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—PTHLH—osteoporosis	0.000274	0.000675	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—POMC—osteoporosis	0.000272	0.000671	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—RAP1A—osteoporosis	0.000271	0.000669	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—LEP—osteoporosis	0.000269	0.000663	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—PTHLH—osteoporosis	0.000268	0.000661	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—P4HB—osteoporosis	0.000266	0.000655	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CALCA—osteoporosis	0.000261	0.000645	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GAPDH—osteoporosis	0.000261	0.000643	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	0.000259	0.00064	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MGLL—osteoporosis	0.000256	0.000632	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	0.000256	0.000631	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—POMC—osteoporosis	0.000255	0.000629	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ENO1—osteoporosis	0.000255	0.000628	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—RAP1A—osteoporosis	0.000254	0.000626	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MGLL—osteoporosis	0.000251	0.000619	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PSMA2—osteoporosis	0.000251	0.000619	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PSMA5—osteoporosis	0.000251	0.000619	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CALCR—osteoporosis	0.000249	0.000615	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTH1R—osteoporosis	0.000249	0.000615	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PTH—osteoporosis	0.000244	0.000602	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CALCA—osteoporosis	0.000241	0.000594	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CNR2—osteoporosis	0.000238	0.000586	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KL—osteoporosis	0.000237	0.000586	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000237	0.000584	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CALCA—osteoporosis	0.000236	0.000582	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—POMC—osteoporosis	0.000232	0.000571	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6R—osteoporosis	0.000226	0.000557	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PTH—osteoporosis	0.000222	0.000546	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000221	0.000546	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ENO1—osteoporosis	0.000219	0.000541	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000216	0.000534	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PSMA2—osteoporosis	0.000216	0.000533	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PSMA5—osteoporosis	0.000216	0.000533	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CNR2—osteoporosis	0.000216	0.000533	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000213	0.000527	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SOST—osteoporosis	0.000211	0.00052	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—POMC—osteoporosis	0.000208	0.000514	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SOST—osteoporosis	0.000206	0.000509	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ENO1—osteoporosis	0.000205	0.000506	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CYP19A1—osteoporosis	0.000204	0.000502	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—WNT1—osteoporosis	0.000203	0.000501	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PSMA2—osteoporosis	0.000202	0.000499	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PSMA5—osteoporosis	0.000202	0.000499	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PTHLH—osteoporosis	0.000202	0.000499	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MGLL—osteoporosis	0.000198	0.000488	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LRP5—osteoporosis	0.000193	0.000476	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTH1R—osteoporosis	0.000191	0.00047	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CALCR—osteoporosis	0.000191	0.00047	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PTH—osteoporosis	0.000187	0.00046	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CALCR—osteoporosis	0.000187	0.00046	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTH1R—osteoporosis	0.000187	0.00046	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ADCY5—osteoporosis	0.000186	0.000459	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LRP6—osteoporosis	0.000185	0.000456	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PTHLH—osteoporosis	0.000184	0.000453	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PTH—osteoporosis	0.000183	0.000451	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CNR2—osteoporosis	0.000182	0.000449	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SPP1—osteoporosis	0.00018	0.000444	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CNR2—osteoporosis	0.000178	0.000439	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CALCA—osteoporosis	0.000178	0.000439	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP19A1—osteoporosis	0.000175	0.000433	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PTH—osteoporosis	0.000169	0.000418	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ADCY5—osteoporosis	0.000166	0.00041	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PTH—osteoporosis	0.000166	0.000409	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GPX1—osteoporosis	0.000166	0.000409	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000166	0.000408	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CNR2—osteoporosis	0.000165	0.000407	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—POMC—osteoporosis	0.000165	0.000406	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP19A1—osteoporosis	0.000164	0.000405	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IRS2—osteoporosis	0.000163	0.000401	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000162	0.0004	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CNR2—osteoporosis	0.000162	0.000399	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CALCA—osteoporosis	0.000162	0.000399	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—LEP—osteoporosis	0.000159	0.000393	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TLN1—osteoporosis	0.000156	0.000385	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—POMC—osteoporosis	0.000156	0.000385	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—WNT1—osteoporosis	0.000155	0.000383	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PTHLH—osteoporosis	0.000155	0.000382	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—MTHFR—osteoporosis	0.000153	0.000377	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ESR1—osteoporosis	0.000152	0.000375	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—WNT1—osteoporosis	0.000152	0.000375	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MGLL—osteoporosis	0.000151	0.000374	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PTHLH—osteoporosis	0.000151	0.000373	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MGLL—osteoporosis	0.000148	0.000366	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LRP5—osteoporosis	0.000148	0.000365	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PKM—osteoporosis	0.000147	0.000363	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FDPS—osteoporosis	0.000147	0.000363	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LRP5—osteoporosis	0.000145	0.000357	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ADCY5—osteoporosis	0.000143	0.000354	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GPX1—osteoporosis	0.000143	0.000352	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IRS1—osteoporosis	0.000142	0.00035	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LRP6—osteoporosis	0.000141	0.000349	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PTHLH—osteoporosis	0.00014	0.000346	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PGLS—osteoporosis	0.000139	0.000344	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPD2—osteoporosis	0.000139	0.000344	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LRP6—osteoporosis	0.000138	0.000341	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PTHLH—osteoporosis	0.000137	0.000339	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—POMC—osteoporosis	0.000137	0.000337	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CALCA—osteoporosis	0.000136	0.000336	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—P4HB—osteoporosis	0.000135	0.000332	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ADCY5—osteoporosis	0.000134	0.000331	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—IL6—osteoporosis	0.000134	0.000331	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GPX1—osteoporosis	0.000134	0.00033	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6R—osteoporosis	0.000133	0.000329	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CALCA—osteoporosis	0.000133	0.000329	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—MTHFR—osteoporosis	0.000132	0.000325	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IGF1—osteoporosis	0.000132	0.000325	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTH—osteoporosis	0.000131	0.000323	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RAP1A—osteoporosis	0.000129	0.000317	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CNR2—osteoporosis	0.000128	0.000315	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ATIC—osteoporosis	0.000127	0.000314	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PNP—osteoporosis	0.000127	0.000314	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—ADCY5—osteoporosis	0.000127	0.000312	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—POMC—osteoporosis	0.000126	0.000311	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFATC1—osteoporosis	0.000125	0.000309	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—DKK1—osteoporosis	0.000124	0.000307	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CALCA—osteoporosis	0.000124	0.000305	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—POMC—osteoporosis	0.000123	0.000304	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—MTHFR—osteoporosis	0.000123	0.000304	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—POMC—osteoporosis	0.000122	0.000302	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CALCA—osteoporosis	0.000121	0.000299	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—WNT1—osteoporosis	0.00012	0.000296	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TLN1—osteoporosis	0.000119	0.000294	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TLN1—osteoporosis	0.000117	0.000288	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGA—osteoporosis	0.000117	0.000288	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—ADCY5—osteoporosis	0.000115	0.000284	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTHLH—osteoporosis	0.000108	0.000267	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—BMP2—osteoporosis	0.000108	0.000267	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—OXCT1—osteoporosis	0.000108	0.000267	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CA2—osteoporosis	0.000108	0.000267	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGB—osteoporosis	0.000106	0.000262	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MGLL—osteoporosis	0.000106	0.000261	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—POMC—osteoporosis	0.000105	0.00026	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—P4HB—osteoporosis	0.000103	0.000254	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—osteoporosis	0.000103	0.000253	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PSMA2—osteoporosis	0.000102	0.000253	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PSMA5—osteoporosis	0.000102	0.000253	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—P4HB—osteoporosis	0.000101	0.000249	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—osteoporosis	0.000101	0.000248	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—osteoporosis	0.0001	0.000248	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTH—osteoporosis	0.0001	0.000247	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—POMC—osteoporosis	9.86e-05	0.000243	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RAP1A—osteoporosis	9.84e-05	0.000243	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTH—osteoporosis	9.8e-05	0.000242	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CNR2—osteoporosis	9.76e-05	0.000241	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—ADCY5—osteoporosis	9.69e-05	0.000239	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RAP1A—osteoporosis	9.63e-05	0.000238	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFATC1—osteoporosis	9.6e-05	0.000237	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CNR2—osteoporosis	9.55e-05	0.000236	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CALCA—osteoporosis	9.55e-05	0.000235	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—DKK1—osteoporosis	9.52e-05	0.000235	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	9.51e-05	0.000235	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—ADCY5—osteoporosis	9.48e-05	0.000234	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFATC1—osteoporosis	9.39e-05	0.000232	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DKK1—osteoporosis	9.32e-05	0.00023	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—POMC—osteoporosis	9.31e-05	0.00023	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—WNT1—osteoporosis	9.17e-05	0.000226	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—IDH2—osteoporosis	8.98e-05	0.000222	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—WNT1—osteoporosis	8.98e-05	0.000222	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGA—osteoporosis	8.92e-05	0.00022	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ADCY5—osteoporosis	8.8e-05	0.000217	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGA—osteoporosis	8.73e-05	0.000215	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KL—osteoporosis	8.67e-05	0.000214	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ADCY5—osteoporosis	8.61e-05	0.000212	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—POMC—osteoporosis	8.45e-05	0.000209	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP27A1—osteoporosis	8.44e-05	0.000208	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTHLH—osteoporosis	8.3e-05	0.000205	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BMP2—osteoporosis	8.3e-05	0.000205	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6R—osteoporosis	8.25e-05	0.000203	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ACP5—osteoporosis	8.21e-05	0.000203	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTHLH—osteoporosis	8.12e-05	0.0002	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BMP2—osteoporosis	8.12e-05	0.0002	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGB—osteoporosis	8.12e-05	0.0002	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGB—osteoporosis	7.95e-05	0.000196	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—osteoporosis	7.91e-05	0.000195	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TGFB1—osteoporosis	7.89e-05	0.000195	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PSMA5—osteoporosis	7.84e-05	0.000193	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PSMA2—osteoporosis	7.84e-05	0.000193	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PSMA2—osteoporosis	7.67e-05	0.000189	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PSMA5—osteoporosis	7.67e-05	0.000189	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TPI1—osteoporosis	7.64e-05	0.000188	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CALCA—osteoporosis	7.3e-05	0.00018	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—P4HB—osteoporosis	7.18e-05	0.000177	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CALCA—osteoporosis	7.15e-05	0.000176	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—POMC—osteoporosis	7.12e-05	0.000176	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GAPDH—osteoporosis	7.05e-05	0.000174	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—POMC—osteoporosis	6.97e-05	0.000172	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RAP1A—osteoporosis	6.86e-05	0.000169	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADCY5—osteoporosis	6.79e-05	0.000168	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KL—osteoporosis	6.63e-05	0.000164	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SPP1—osteoporosis	6.57e-05	0.000162	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KL—osteoporosis	6.49e-05	0.00016	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—POMC—osteoporosis	6.47e-05	0.00016	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—POMC—osteoporosis	6.33e-05	0.000156	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6R—osteoporosis	6.31e-05	0.000156	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6R—osteoporosis	6.18e-05	0.000152	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—osteoporosis	5.94e-05	0.000147	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS2—osteoporosis	5.94e-05	0.000147	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LEP—osteoporosis	5.81e-05	0.000143	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ESR1—osteoporosis	5.55e-05	0.000137	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ENO1—osteoporosis	5.55e-05	0.000137	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PSMA2—osteoporosis	5.47e-05	0.000135	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PSMA5—osteoporosis	5.47e-05	0.000135	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADCY5—osteoporosis	5.2e-05	0.000128	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS1—osteoporosis	5.19e-05	0.000128	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADCY5—osteoporosis	5.08e-05	0.000125	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SPP1—osteoporosis	5.03e-05	0.000124	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—POMC—osteoporosis	4.99e-05	0.000123	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SPP1—osteoporosis	4.92e-05	0.000121	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6R—osteoporosis	4.87e-05	0.00012	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—osteoporosis	4.8e-05	0.000119	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS2—osteoporosis	4.55e-05	0.000112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS2—osteoporosis	4.45e-05	0.00011	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—osteoporosis	4.45e-05	0.00011	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP19A1—osteoporosis	4.44e-05	0.000109	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—osteoporosis	4.35e-05	0.000107	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—osteoporosis	4.25e-05	0.000105	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—osteoporosis	4.16e-05	0.000103	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS1—osteoporosis	3.97e-05	9.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS1—osteoporosis	3.88e-05	9.58e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—POMC—osteoporosis	3.82e-05	9.43e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—POMC—osteoporosis	3.74e-05	9.23e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6R—osteoporosis	3.73e-05	9.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—osteoporosis	3.68e-05	9.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—osteoporosis	3.67e-05	9.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6R—osteoporosis	3.65e-05	9e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ADCY5—osteoporosis	3.62e-05	8.94e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPX1—osteoporosis	3.61e-05	8.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—osteoporosis	3.6e-05	8.88e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—osteoporosis	3.33e-05	8.22e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—osteoporosis	2.89e-05	7.12e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—osteoporosis	2.88e-05	7.11e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—osteoporosis	2.81e-05	6.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—osteoporosis	2.75e-05	6.79e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POMC—osteoporosis	2.67e-05	6.58e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—osteoporosis	2.21e-05	5.45e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—osteoporosis	2.2e-05	5.44e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—osteoporosis	2.17e-05	5.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—osteoporosis	2.16e-05	5.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—osteoporosis	2.16e-05	5.32e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—osteoporosis	1.66e-05	4.1e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—osteoporosis	1.63e-05	4.01e-05	CbGpPWpGaD
